Kroger Specialty Pharmacy Recalls Tasigna Capsules Due to Processing Controls
Kroger Specialty Pharmacy is recalling Tasigna Capsules 150 mg due to a lack of processing controls. The affected units were dispensed in five states between December 2017 and February 2018.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text identifies this as an FDA Class II recall. According to the severity rubric, FDA Class II recalls are classified as Severe (Score 4), particularly when specific injury reports are not explicitly detailed but the classification itself warrants a higher severity level than Moderate.
Plain-English summary
Kroger Specialty Pharmacy, Inc. is recalling Tasigna Capsules 150 mg (NDC 00078-0592-87, 28-day supply) because of a lack of processing controls. This FDA Class II recall involves all lots remaining within expiry that were dispensed between December 1, 2017, and February 12, 2018.
The affected products were distributed in Mississippi, Louisiana, Arkansas, Illinois, and Florida. The recall is classified as Class II, which indicates that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for further instructions. No specific illness or injury reports are mentioned in the source text.
The recalled product
- Product
- Tasigna Capsules 150 mg NDC 00078-0592-87 28 days supply
- Manufacturer
- Kroger Specialty Pharmacy, Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry dispensed 12/01/2017 through 02/12/2018
Distribution
Part of a larger recall action
This product is one of 67 recalled by Kroger Specialty Pharmacy, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same manufacturer · Kroger Specialty Pharmacy, Inc.
See all →- HighKroger Recalls Botox Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- HighKroger Recalls Capecitabine Tablets Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateKroger Specialty Pharmacy Recalls Cimzia 200 mg/mL PFS Kits
FDA (Drugs) · 2018-05-16
- HighKroger Recalls Lupron Depot Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- ModerateKroger Specialty Pharmacy Recalls Cyclophosphamide Capsules Due to Processing Controls
FDA (Drugs) · 2018-05-16
Same hazard · processing controls
See all →- HighCompounded tirzepatide 8.8 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded tirzepatide 11.24 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded semaglutide 0.22 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded semaglutide 0.44 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13
- HighCompounded tirzepatide 4.4 mg vials recalled over lack of processing controls
FDA (Drugs) · 2025-08-13